A New Milestone for Breast Cancer Care: Cryoablation is Now FDA-Cleared for Low-Risk Patients 

Becoming the first-and-only medical device to be FDA approved for low-risk breast cancer, ProSense® cryoablation is poised to be a game changer to provide minimally invasive treatment for appropriately selected patients.

A step forward towards cryoablation for early-stage breast cancer: Final 5-year results of the ICE3 trial

Researchers are consistently pushing back the boundaries of what is possible for the treatment of breast cancer. Results of one of the most exciting and innovative trials in breast cancer, the ICE3 Trial on cryoablation of early stage, low-risk breast cancer, were recently published in the Annals of Surgical Oncology by Dr. Richard Fine. In […]